As of June 30, 2026, Inection Point Acquisition Corp. VII carries a market capitalization of 317.70M, placing it among publicly traded companies globally. Its enterprise value stands at 316.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 317.70M |
| Enterprise Value | 316.62M |
Inection Point Acquisition Corp. VII's next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of June 30, 2026, Inection Point Acquisition Corp. VII has 31.33M shares outstanding.
| Shares Outstanding | 31.33M |
As of June 30, 2026, Inection Point Acquisition Corp. VII trades at a trailing price-to-earnings ratio of 244.72.
| PE Ratio | 244.72 |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | -769.76 |
| P/OCF Ratio | -766.58 |
As of June 30, 2026, Inection Point Acquisition Corp. VII maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.79 |
| Quick Ratio | 0.68 |
These figures cover the twelve months ended June 30, 2026. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.
| Employee Count | 2.00 |
As of the close on November 16, 2026, Inection Point Acquisition Corp. VII's stock has declined approximately 4.00% over the past 52 weeks. The 50-day moving average sits at 10.11, while the 200-day moving average is 10.17.
| 52-Week Price Change | -4.00% |
| 50-Day Moving Average | 10.11 |
| 200-Day Moving Average | 10.17 |
Over the twelve months ended June 30, 2026, Inection Point Acquisition Corp. VII generated - - in revenue and converted that into 1.18M in net income, yielding earnings per share of 0.04. EBITDA reached -1.92M, while operating income came in at -1.92M.
| Operating Income | -1.92M |
| Pretax Income | 1.18M |
| Net Income | 1.18M |
| EBITDA | -1.92M |
| EBIT | -1.92M |
| Earnings Per Share (EPS) | 0.04 |
These figures are as of June 30, 2026. Total book value stands at 232.83M, with working capital of -343,967.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.09M |
| Net Debt | -1.09M |
| Equity (Book Value) | 232.83M |
| Book Value Per Share | 7.43 |
| Working Capital | -343,967.00 |
Inection Point Acquisition Corp. VII produced -375,953.00 in operating cash flow over the twelve months ended June 30, 2026.
| Operating Cash Flow | -375,953.00 |
| Free Cash Flow | -375,953.00 |
| FCF Per Share | -0.01 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.
| FCF Yield | -0.13 |
As of June 30, 2026, Inection Point Acquisition Corp. VII has an Altman Z-Score of 118.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 118.73 |